A partnering agreement between US-based market access consultancy PRO-spectus and Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) will drive marketing, market access, and reimbursement of LDX's flagship point-of-care diagnostic, FebriDx®.
With US Medicare reimbursement already in place, Lumos is now focused on securing coverage from private insurance payors, which make up around 60% of the US health insurance market and cover more than 170 million Americans. This includes both major insurers controlling nearly half the market and hundreds of smaller players requiring a targeted approach.
"This partnership with PRO-spectus is an important step in accelerating the commercial adoption of FebriDx® in the US market," Lumos CEO Doug Ward said. "By combining our clinically proven diagnostic technology with PRO-spectus' market access expertise, we can better equip healthcare providers to secure reimbursement and accelerate the adoption of FebriDx®. Ultimately, this means reducing unnecessary antibiotic use, improving patient outcomes, and helping to address the growing challenge of antimicrobial resistance."
The agreement will run until December 2026.
Strategic support to expand adoption and reimbursement
Under the agreement, PRO-spectus will deliver a suite of strategic and operational services aimed at accelerating patient access to FebriDx®.
Services include market access consulting to communicate the test's clinical and economic value, a dedicated reimbursement helpline for coding and payment queries, and field-based access and reimbursement managers to work directly with strategic accounts.
These functions will integrate with Lumos' sales team to equip healthcare providers with the tools, education, and hands-on support needed to adopt FebriDx® and secure reliable reimbursement from insurers.
The collaboration seeks to broaden patient access, improve clinical decision-making and support healthcare system efficiency.
PRO-spectus chief operating officer Danica Carlson said her company was "thrilled" to support FebriDx®'s US expansion.
"Our team is dedicated to helping patients receive access to rapid, accurate diagnosis of their symptoms, supporting provider care decisions that avoid unnecessary antibiotic use and promote better long-term health. FebriDx® represents a meaningful advancement in respiratory infection management, and we're proud to help bring it to more communities," Carlson said.
About FebriDx® and Lumos Diagnostics
FebriDx® is a rapid point-of-care test that differentiates between bacterial and non-bacterial respiratory infections in approximately 10 minutes, aiding clinical decision-making and potentially reducing unnecessary antibiotic prescribing.
Lumos Diagnostics develops, manufactures, and commercialises rapid point-of-care diagnostic technologies targeting infectious and inflammatory diseases. The company also offers customised assay development, manufacturing services, and proprietary digital reader platforms for the global healthcare market.